• Wei Hao, You-Yang Shi, Yue-Nong Qin, Chen-Ping Sun, Li-Ying Chen, Chun-Yu Wu, Yi-Jia Bao, and Sheng Liu.
• Department of Breast Surgery (Integrated Traditional and Western Medicine), Long Hua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
• Medicine (Baltimore). 2022 Jul 29; 101 (30): e29691e29691.

BackgroundTo assess the benefits and harmful effects of Chinese herbal medicine (CHM) formulations in preventing anthracyclines (ANT)-induced cardiotoxicity.MethodThe Cochrane Library, Pubmed and EMBASE databases were electronically searched for relevant randomized controlled trials (RCTs) published till December 2021 in English or Chinese-language, in addition to manual searches through the reference lists of the selected papers, and the Chinese Conference Papers Database. Data was extracted by 2 investigators independently.ResultSeventeen RCTs reporting 11 different CHMs were included in this meta-analysis. The use of CHM reduced the occurrence of clinical heart failure (RR 0.48, 95% CI 0.39 to 0.60, P < .01) compared to the control group. Data on subclinical heart failure in terms of LVEF values showed that CHM reduced the occurrence of subclinical heart failure (RR 0.47, 95% CI 0.35 to 0.62, P < .01) as well.ConclusionCHM is an effective and safe cardioprotective intervention that can potentially prevent ANT-induced cardiotoxicity. However, due to the insufficient quality of the included trials, our results should be interpreted with cautious.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

25 keywords...

hide…